Evaluating a new PET/CT imaging method for tumors
Clinical Evaluation of 18F-FAPI-RGD PET/CT for Imaging of Fibroblast Activation Protein and Integrin avb3 in Various Tumor Types
Sichuan Provincial People's Hospital · NCT06094530
This study is testing a new type of PET/CT imaging to see if it works better than the standard method for finding tumors in 100 patients with different types of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 10 Years to 80 Years |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital (other) |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06094530 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the clinical feasibility of 18F-FAPI-RGD PET/CT imaging in 100 patients with various types of tumors. The study will compare the radiotracer uptake and diagnostic performance of 18F-FAPI-RGD PET/CT against the established 18F-FDG PET/CT. Results will be validated by comparing PET imaging findings with histopathologic results from surgeries or biopsies, and clinical follow-up data when tissue diagnosis is not applicable.
Who should consider this trial
Good fit: Ideal candidates include patients with clinically suspected or diagnosed tumors.
Not a fit: Patients with uncontrolled hypertension, chronic liver disease, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of tumor imaging and diagnosis for patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving tumor imaging techniques.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinically suspected or diagnosed tumors Exclusion Criteria: * Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg * Complicated with chronic liver disease, myocardial infarction, stroke * Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception * Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
Where this trial is running
Chengdu, Sichuan
- Departments of Nuclear Medicine, Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (RECRUITING)
Study contacts
- Study coordinator: Hao Wang, Doctor
- Email: 474556259@qq.com
- Phone: +86-18313820216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasms